Five to buy
Dechra Pharmaceuticals
The Mail on Sunday This veterinary-medicines provider may sell “equine sedatives”, but its recent performance has still managed to “scare the horses”. Investors are nervous as a pandemic-era pet-buying boom wanes and farming heads for a difficult period. But the sell-off looks “overdone”. Spending on pets tends to be resilient in recessions, while Dechra’s drugs pipeline, including “long-acting dog insulin”, heralds future growth. It’s “a buying opportunity for the brave”. 2,756p